ReviewCurrent atherosclerosis reports2013
Advances in pharmacologic therapies for type 2 diabetes.
Review in Current atherosclerosis reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 18 citations in OpenAlex.
- Trial
- Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer's disease.Archives of pharmacal research · 2020Review
- New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer's Disease.Metabolic brain disease · 2018 · on this mapReview
- Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38).Journal of diabetes investigation · 2016 · on this mapObservational
- The functional activity of hypothalamic signaling systems in rats with neonatal diabetes mellitus treated with metformin.Doklady. Biochemistry and biophysics · 2016Article
- Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia.Frontiers in endocrinology · 2014Review
- Potent DGAT1 Inhibitors in the Benzimidazole Class with a Pyridyl-oxy-cyclohexanecarboxylic Acid Moiety.ACS medicinal chemistry letters · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes (T2DM) is a multi-causal, heterogeneous and progressive cardiometabolic condition, with an increasing prevalence worldwide. T2DM is associated with multiple comorbidities that may impact patients' quality of life. Treatment is multifactorial, but pharmacologic treatment of hyperglycemia is still regarded as the mainstay of diabetes management. Current established therapies include metformin, sulfonylurea agents and insulin, the long-term use of which was associated with reduced micro- and macrovascular events in the United Kingdom Prospective Diabetes Study. Despite major recent advances in diabetes care, a large proportion of patients remain in poor glycemic control, necessitating the development of new therapeutic options. The recently published position statement of the American Diabetes Association and European Association for the Study of Diabetes for the management of hyperglycemia in T2DM has accommodated this wider range of therapy choices, as it is less prescriptive and advocates an individualized treatment approach, taking into account many relevant patient- and disease-related factors. This review summarizes the updates on various established agents as well as the recent developments with regard to incretin-based therapies, inhibitors of the renal tubular sodium-glucose-linked-transporter-2 and ultra-long acting basal insulin formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.